Accelerating Radioiodine Therapy in Differentiated Thyroid Cancer: A Novel 24-Hour Diagnostic 131I Scan Protocol Post-rhTSH Administration

MedXY Editorial Team•Aug 25, 2026•Diabetes & Endocrinology

Implementation of diagnostic 131I whole-body scans within 24 hours after the second recombinant human thyrotropin (rhTSH) injection is feasible and reliable in differentiated thyroid cancer (DTC) patients.
High concordance rates (over 90%) between early diagnostic scans at 18 and 24 hours versus post-therapy scans support immediate pre-treatment disease evaluation.
Serum thyroglobulin (sTg) measurements at 24 hours post-rhTSH correlate strongly with 72-hour levels, reflecting consistent biochemical disease status.
This accelerated protocol enables radioiodine therapy (RAIT) within the same two-injection rhTSH cycle, potentially reducing costs and improving clinical workflow.

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Implementation of diagnostic 131I whole-body scans within 24 hours after the second recombinant human thyrotropin (rhTSH) injection is feasible and reliable in differentiated thyroid cancer (DTC) patients.
High concordance rates (over 90%) between early diagnostic scans at 18 and 24 hours versus post-therapy scans support immediate pre-treatment disease evaluation.
Serum thyroglobulin (sTg) measurements at 24 hours post-rhTSH correlate strongly with 72-hour levels, reflecting consistent biochemical disease status.
This accelerated protocol enables radioiodine therapy (RAIT) within the same two-injection rhTSH cycle, potentially reducing costs and improving clinical workflow.